Robert Malone on pfizer: what the evidence says · JRE #1757

What the evidence says 01 / RECORD

Maddie de Garay, then 12, was a real participant in Pfizer's 2020-2021 Phase 2/3 trial of BNT162b2 in 12-to-15-year-olds (roughly 1,131 vaccinated adolescents), and she developed a severe, disabling illness after her second dose that has left her using a wheelchair and a feeding tube; this much is documented and undisputed. Pfizer's submission to the FDA classified her adverse event as "functional abdominal pain," a characterization the family's attorney and the family have publicly disputed as understating the severity of her condition, and congressional testimony indicates Pfizer did not disclose the full details of her case (wheelchair, feeding tube) to the FDA until months after onset, following public inquiries. The trial's principal investigator concluded her symptoms were not consistent with a vaccine-related adverse event, a determination that testimony states FDA did not independently challenge. Malone's framing that she "had a seizure" goes beyond the documented record: her family and treating clinicians have described diagnoses of functional neurological disorder and, later, chronic inflammatory demyelinating polyneuropathy (CIDP), not a formally diagnosed seizure disorder, so this specific detail appears to be an exaggeration or imprecise recollection layered onto an otherwise real and well-documented case. Status: mixed; the core injury and the disputed "functional abdominal pain" classification are real and corroborated, but the specific "seizure" detail is not substantiated in the available record.